Gluetacs Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Series A
- Investors
-
12
Gluetacs Therapeutics General Information
Description
Developer of targeted protein degradation technologies designed for oncology and immunotherapy. The company offers molecular glues, bifunctional degraders, and AI-powered drug discovery platforms, providing healthcare providers and the pharmaceutical sector with specialized hardware and oral small-molecule therapies for refractory cancers and autoimmune diseases.
Contact Information
Website
www.gluetacs.comCorporate Office
- Building 20, Lane 218, Haiji Sixth Road
- Pudong New Area
- Shanghai, 201306
- China
Corporate Office
- Building 20, Lane 218, Haiji Sixth Road
- Pudong New Area
- Shanghai, 201306
- China
Gluetacs Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Early Stage VC (Series A) | 04-Jan-2024 | Completed | Generating Revenue | |||
| 5. Early Stage VC | 03-Jul-2022 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 11-Nov-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 22-Mar-2021 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Dec-2020 | Completed | Startup | |||
| 1. Seed Round | 01-Nov-2020 | Completed | Startup |
Gluetacs Therapeutics Signals
Gluetacs Therapeutics Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Gortune Investment | Venture Capital | Minority | ||
| Huangpu Biomedical Industry Investment Fund | Growth/Expansion | Minority | ||
| Leading Capital Company | Asset Manager | Minority | ||
| Shanghai Sinan Yuanke Private Equity Fund Management | Growth/Expansion | Minority | ||
| In Capital | Venture Capital | Minority |
Gluetacs Therapeutics FAQs
-
When was Gluetacs Therapeutics founded?
Gluetacs Therapeutics was founded in 2020.
-
Where is Gluetacs Therapeutics headquartered?
Gluetacs Therapeutics is headquartered in Shanghai, China.
-
What is the size of Gluetacs Therapeutics?
Gluetacs Therapeutics has 20 total employees.
-
What industry is Gluetacs Therapeutics in?
Gluetacs Therapeutics’s primary industry is Biotechnology.
-
Is Gluetacs Therapeutics a private or public company?
Gluetacs Therapeutics is a Private company.
-
What is Gluetacs Therapeutics’s current revenue?
The current revenue for Gluetacs Therapeutics is .
-
How much funding has Gluetacs Therapeutics raised over time?
Gluetacs Therapeutics has raised $22.5M.
-
Who are Gluetacs Therapeutics’s investors?
Gortune Investment, Huangpu Biomedical Industry Investment Fund, Leading Capital Company, Shanghai Sinan Yuanke Private Equity Fund Management, and In Capital are 5 of 12 investors who have invested in Gluetacs Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process